Gaithersburg-Based Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Per Novavax:
Novavax
Gaithersburg-Based Novavax Reaches Agreement to Provide 1.1 Billion Doses of Covid Vaccine Candidate Globally
Per Novavax:
Gaithersburg-Based Novavax Releases Covid Vaccine Trial Data
Novavax conducted a 15,000-person trial in the United Kingdom, and their early analysis suggests 90 percent efficacy after a two-dose regimen. The two vaccines that have received FDA Emergency Use Authorization (EUA), Pfizer and Moderna, have 95 percent and 94 percent efficacy after two doses, respectively. Unlike Pfizer and Moderna’s vaccines, which require varying levels of freezer storage, the Novavax vaccine is stable long-term in the refrigerator.